Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Gene Variant Descriptions||ALK G1269A lies within the protein kinase domain of the Alk protein (UniProt.org). G1269A has been demonstrated to occur as a secondary resistance mutation in the context of ALK rearrangement (PMID: 30675302, PMID: 28434515, PMID: 29872693), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2022).|
|Associated Drug Resistance||Y|
|Category Variants Paths||
ALK mutant ALK G1269A
|Transcript||gDNA||cDNA||Protein||Source Database||Genome Build|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ALK G1269A||Advanced Solid Tumor||sensitive||Brigatinib||Preclinical - Cell culture||Actionable||In a preclinical study, a transformed cell line expressing ALK G1269A was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).||27049722|
|ALK G1269A||Advanced Solid Tumor||predicted - sensitive||TPX-0131||Preclinical - Biochemical||Actionable||In a preclinical study, TPX-0131 inhibited kinase activity of ALK G1269A in an in vitro assay (PMID: 34158340).||34158340|
|ALK G1269A||Advanced Solid Tumor||predicted - sensitive||APG-2449||Preclinical - Biochemical||Actionable||In a preclinical study, APG-2449 inhibited the kinase activity of ALK G1269A in culture (PMID: 35820889).||35820889|